BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 20371394)

  • 21. Hypereosinophilic syndromes.
    Roufosse FE; Goldman M; Cogan E
    Orphanet J Rare Dis; 2007 Sep; 2():37. PubMed ID: 17848188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mepolizumab treatment for asthma.
    Robinson DS
    Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.
    Kay AB; Klion AD
    Immunol Allergy Clin North Am; 2004 Nov; 24(4):645-66, vii. PubMed ID: 15474864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.
    Oldhoff JM; Darsow U; Werfel T; Katzer K; Wulf A; Laifaoui J; Hijnen DJ; Plötz S; Knol EF; Kapp A; Bruijnzeel-Koomen CA; Ring J; de Bruin-Weller MS
    Allergy; 2005 May; 60(5):693-6. PubMed ID: 15813818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.
    Assa'ad AH; Gupta SK; Collins MH; Thomson M; Heath AT; Smith DA; Perschy TL; Jurgensen CH; Ortega HG; Aceves SS
    Gastroenterology; 2011 Nov; 141(5):1593-604. PubMed ID: 21835135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5.
    Stein ML; Rothenberg ME
    Expert Rev Clin Immunol; 2005 Nov; 1(4):633-44. PubMed ID: 20477604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Anti-interleukin-5 therapy for eosinophilic diseases].
    Simon D; Braathen LR; Simon HU
    Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mepolizumab-based therapy in asthma: an update.
    Walsh GM
    Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):392-6. PubMed ID: 26110690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mepolizumab in the treatment of severe eosinophilic asthma.
    Fainardi V; Pisi G; Chetta A
    Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
    Roufosse FE; Kahn JE; Gleich GJ; Schwartz LB; Singh AD; Rosenwasser LJ; Denburg JA; Ring J; Rothenberg ME; Sheikh J; Haig AE; Mallett SA; Templeton DN; Ortega HG; Klion AD
    J Allergy Clin Immunol; 2013 Feb; 131(2):461-7.e1-5. PubMed ID: 23040887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [An investigation of the clinical utility of serum interleukin-5 measurements in bronchial asthma patients].
    Onizuka R; Ishibatake H; Tanaka M; Kumamoto K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Nov; 35(11):1215-22. PubMed ID: 9493449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
    Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
    J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.
    Smith DA; Minthorn EA; Beerahee M
    Clin Pharmacokinet; 2011 Apr; 50(4):215-27. PubMed ID: 21348536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.
    Gevaert P; Van Bruaene N; Cattaert T; Van Steen K; Van Zele T; Acke F; De Ruyck N; Blomme K; Sousa AR; Marshall RP; Bachert C
    J Allergy Clin Immunol; 2011 Nov; 128(5):989-95.e1-8. PubMed ID: 21958585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.
    Plötz SG; Simon HU; Darsow U; Simon D; Vassina E; Yousefi S; Hein R; Smith T; Behrendt H; Ring J
    N Engl J Med; 2003 Dec; 349(24):2334-9. PubMed ID: 14668459
    [No Abstract]   [Full Text] [Related]  

  • 37. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders.
    Heinisch IV; Bizer C; Volgger W; Simon HU
    J Allergy Clin Immunol; 2001 Jul; 108(1):21-8. PubMed ID: 11447378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential expression of the interleukin 5 receptor alpha isoforms in blood and tissue eosinophils of nasal polyp patients.
    Gevaert P; Hellman C; Lundblad L; Lundahl J; Holtappels G; van Cauwenberge P; Tavernier J; Bachert C
    Allergy; 2009 May; 64(5):725-32. PubMed ID: 19170670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
    Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-5 mRNA levels in blood and bone marrow mononuclear cells from patients with the idiopathic hypereosinophilic syndrome.
    Satoh T; Sun L; Li MS; Spry CJ
    Immunology; 1994 Oct; 83(2):308-12. PubMed ID: 7835952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.